Micardis and Mydriasis - a phase IV clinical study of FDA data

Summary:

Mydriasis is reported as a side effect among people who take Micardis (telmisartan), especially for people who are female, 50-59 old, also take Carboplatin, and have Asthma.

The phase IV clinical study analyzes which people have Mydriasis when taking Micardis. It is created by eHealthMe based on reports of 26,556 people who have side effects when taking Micardis from the FDA, and is updated regularly.

What is Micardis?

Micardis has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 27,605 Micardis users. Check the latest studies of Micardis.

What is Mydriasis?

Mydriasis (a dilation of the pupil) is found to be associated with 796 drugs and 1,152 conditions by eHealthMe. Check the latest studies of Mydriasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

26,556 people reported to have side effects when taking Micardis.
Among them, 13 people (0.05%) have Mydriasis.

Among these 13 people:

What is the gender of people who have Mydriasis when taking Micardis? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Mydriasis when taking Micardis? *

What are other drugs people take besides Micardis? *

What are other side effects people have besides Mydriasis? *

Hypoaesthesia (reduced sense of touch or sensation): 4 people, 30.77%
Visual Brightness: 4 people, 30.77%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 4 people, 30.77%
Blindness Transient (sudden loss of vision): 4 people, 30.77%
Ocular Icterus (presence of jaundice seen in the sclera of the eye): 4 people, 30.77%
Respiration Abnormal (abnormal breathing process): 3 people, 23.08%
Vision Blurred: 3 people, 23.08%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 3 people, 23.08%
Diplopia (double vision): 3 people, 23.08%
Depressed Level Of Consciousness: 3 people, 23.08%

What are the existing conditions these people have? *

Skin Wrinkling (wrinkle on skin): 1 person, 7.69%
Rashes (redness): 1 person, 7.69%
Itching: 1 person, 7.69%
Headache (pain in head): 1 person, 7.69%
Diabetes: 1 person, 7.69%
Asthma: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Micardis and have Mydriasis?

- Check whether Mydriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Micardis:

Micardis (27,605 reports)

Mydriasis treatments and more:

Mydriasis (15,532 reports)

Browse all side effects of Micardis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mydriasis:

Mydriasis (796 drugs)

Browse all the conditions that are associated with Mydriasis:

Mydriasis (1,152 conditions)

Related publications that referenced our studies

Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on telmisartan (the active ingredients of Micardis) and Micardis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.